Lopinavir: the old champion

dc.creatorNunes, Estevão Portela
dc.creatorSantini-Oliveira, Marília
dc.creatorGrinsztejn, Beatriz
dc.date2018-11-19T11:47:49Z
dc.date2018-11-19T11:47:49Z
dc.date2011
dc.date.accessioned2023-09-26T20:18:43Z
dc.date.available2023-09-26T20:18:43Z
dc.identifierNUNES, E. P.; DE OLIVEIRA, M. S.; GRINSTEJN, B. Lopinavir: the old champion. Future Virology, v. 6, n. 5, p. 561-570, 2011.
dc.identifier1746-0794
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/30083
dc.identifier10.2217/FVL.11.34
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8853939
dc.descriptionLopinavir/ritonavir approval for use in antiretroviral treatment 10 years ago was very important for the recognition of boosted protease inhibitor (PI)-based therapy as an attractive option for first-line therapy. Being coformulated with ritonavir and having less toxicity than former PIs it allowed for effective and durable virologic suppression with less impact on quality of life. It soon became the standard of care for salvage therapy in its class. Since then, however, its central role has been challenged by new PIs with a more favorable impact on lipid profile, better gastrointestinal tolerability or that are more active in the setting of multidrug resistance. This article summarizes the main clinical studies with lopinavir and discusses its particular characteristics as well as its possible current role in antiretroviral therapy.
dc.description2021-08-30
dc.formatapplication/pdf
dc.languageeng
dc.rightsrestricted access
dc.subjectAntiretroviral therapy
dc.subjectLopinavir
dc.subjectProtease inhibitors
dc.titleLopinavir: the old champion
dc.typeArticle


Este ítem pertenece a la siguiente institución